Rigel Pharma Has More Room To Run Seeking Alpha Rigel also has R333 queued up for Phase 2 studies in discoid lupus, as well as R548 in Phase 1 for transplant rejection. Behind these are several preclinical programs including a GDF8 inhibitor and an AMPK activator. I'm rarely very positive about ... |
